Elixiron Immunotherapeutics
Biotechnology Research • 
17F, No. 3 Park Street, Taiwan, Province of China • 11-20 Employees
Company overview
| Headquarters | 17F, No. 3 Park Street, Nangang District, Taipei, Shanghai, TW |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Founded | 2017 |
| Employees | 11-20 |
| Socials |
Key Contacts at Elixiron Immunotherapeutics
Ningen Chang
Director Clinical Operations
Sherry Chao
Medical Director
Chen- Hsuan
Director Of Translational Sciences
沛翰 鍾
Associate Director
Huey-Wen Hsiao
Director Of Translational Sciences
Chi Pai
Director, R&D Program Management
Elixiron Immunotherapeutics Email Formats
Elixiron Immunotherapeutics uses 4 email formats. The most common is {first name}{last name} (e.g., johndoe@elixiron.com), used 33.3% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@elixiron.com | 33.3% |
{first initial}.{last name} | j.doe@elixiron.com | 22.2% |
{first name}.{last name} | john.doe@elixiron.com | 22.2% |
{last name} | doe@elixiron.com | 22.2% |
About Elixiron Immunotherapeutics
Elixiron Immunotherapeutics is driven by a multi-cultural, international team in Shanghai, Taipei, the USA (San Francisco) and Switzerland (Lausanne) with a shared vision to build a global company that brings next-generation immunotherapies to patients in need. This vision drives our mission to target rare and immunological diseases as well as cancer for indications that could substantially benefit from advances in immunotherapy approaches. We employ advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody domain phage display library and a single human B cell antibody cloning platform to develop innovative therapies. Our two lead pipeline candidates are in phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF-1R kinase activity, is being explored as a potential therapy for Alzheimer's disease as well as tenosynovial giant cell tumors, and a monoclonal antibody, EI-001 is being developed for the treatment of vitiligo and other immunological disorders.
Elixiron Immunotherapeutics revenue & valuation
| Annual revenue | $2,000,000 |
| Revenue per employee | $100,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $6,400,000 |
| Total funding | $13,800,000 |
Employees by Management Level
Total employees: 11-20
Seniority
Employees
Employees by Department
Elixiron Immunotherapeutics has 4 employees across 3 departments.
Departments
Number of employees
Elixiron Immunotherapeutics Tech Stack
Discover the technologies and tools that power Elixiron Immunotherapeutics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
Operating systems
JavaScript libraries
Web servers
Web frameworks
Maps
Belgium
Saudi Arabia
CanadaFrequently asked questions
4.8
40,000 users
